Overall Objectives

Global Summit on Precision Diagnosis for Prostate Cancer (PC) has been established as the annual public educational conference integrated with ongoing deliberations of the Steering Committee . The mission of this integrated effort is three-fold:

1) To educate the key health care stakeholders about the recent advances in precision diagnostics that are transforming patient care;

2) To bridge the gap between the experts in the in vitro diagnostics (IVD) and in vivo imaging communities by stimulating and maintaining a cross-disciplinary clinical and scientific dialogue; and

3) To expedite transfer of promising innovations from laboratories to clinics through the development of the consensus-based educational, clinical and research strategy.

Background and Rationale

The Steering Committee met on February 16, 2017 and reached consensus that the First Global Summit on Precision Diagnosis for PC brought into a sharp focus:

  • The key importance of precision diagnosis for precision treatment;
  • The current wide inter-disciplinary gap between the in vitro diagnostic (IVD) and in vivo imaging experts – and the need to bridge this gap by developing a consensus-based, integrated, multi-modality approach in order to improve diagnostic evaluation (including risk assessment pre- and post-diagnosis of PC);
  • Recent and rapidly evolving discoveries of genomic alterations in PC (particularly in advanced, lethal, metastatic disease) – and their clinical implications for the development of drugs and diagnostics;
  • The need for clear articulation and validation of clinical utility of diagnostic tools; and
  • The need to expedite clinical evaluation of promising diagnostics and their transfer to patients.

Groundbreaking Potential of Radiogenomics

The First Summit highlighted the emerging area of radiogenomics, which integrates quantitative analysis of non-invasive imaging (radiomics), image-guided histopathology and genomic information, including image-guided genomic tissue profiling. The following preliminary results were presented, discussed and underscored a potentially brekthrough impact of radiogenomics on patient care and research:

  • Adding in vivo imaging to fluid- and tissue-based IVD may improve diagnostic accuracy (including prognostic and predictive assessment); and
  • Interface between in vitro and in vivo tumor targets may advance both IVD and imaging, non-invasive tissue characterization, risk assessment and development of short- and intermediate-term quantitative outcomes for patient care and prospective clinical trials; and
  • While MRI and ultrasound are important for early PC evaluation, molecular imaging (e.g. PET) is valuable for recurrent, locally advanced and metastatic disease. MRI-PET fusion may advance diagnosis of recurrent disease.

Educational Program Highlights

Based on the First Summit, the Steering Committee recommended the following new and/or expanded sessions and related discussion:

  • Radiogenomics
  • Diagnostic solutions to the key clinical challenges in prostate cancer care
  • Improved risk assessment prior to and after diagnosis of prostate cancer
  • Advanced prostate cancer
  • Facilitated transfer of promising technologies from laboratories to clinics (with the focus on reimbursement and related considerations)